Systematic review with meta-analysis: Do interferon lambda 3 polymorphisms predict the outcome of interferon-therapy in hepatitis B infection?

Alimentary Pharmacology and Therapeutics

Volumn 39, Issue 6, 2014, Pages 569-578

  Galmozzi, E ^a   Vigano M ^a   Lampertico, P ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ADENINE NUCLEOTIDE DERIVATIVE; INTERLEUKIN 28B; LAMIVUDINE; PEGINTERFERON ALPHA2A; RIBAVIRIN;

ASIAN; CAUCASIAN; COMBINATION CHEMOTHERAPY; DRUG RESPONSE; ETHNIC DIFFERENCE; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; GENE LOCUS; GENETIC ASSOCIATION; GENOMICS; GENOTYPE; HEPATITIS B; HUMAN; IFNLAMDA3 GENE; META ANALYSIS; MONOTHERAPY; NONHUMAN; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SEROCONVERSION; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMATIC REVIEW; VIRAL CLEARANCE; VIRUS CELL INTERACTION;

ANTIVIRAL AGENTS; GENETIC TESTING; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HEPATITIS B; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HUMANS; INTERFERONS; INTERLEUKINS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84894562959     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12631     Document Type: Review

References (41)

1. World Health Organization. Hepatitis B 2013. Available at: http://www.who.int/mediacentre/factsheets/fs204. Accessed December 2013.
2. Wiersma S,. The global burden of disease of viral hepatitis. Viral Hepat 2011; 19: 9-10.
3. Kuo A, Gish R,. Chronic hepatitis B infection. Clin Liver Dis 2012; 16: 347-69.
4. EASL Clinical Practice Guidelines. Management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167-85.
5. Lok AS, McMahon BJ,. Chronic hepatitis B. Hepatology 2007; 45: 507-39.
6. Liaw YF, Kao JH, Piratvisuth T, et al,. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2012; 6: 531-61.
7. Viganò M, Lampertico P,. Antiviral drugs for HBV liver disease. Expert Opin Biol Ther 2011; 11: 285-300.
8. Lau GK, Piratvisuth T, Luo KX, et al,. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352: 2682-95.
9. Janssen HL, van Zonneveld M, Senturk H, et al,. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005; 365: 123-9.
10. Marcellin P, Lau GK, Bonino F, et al,. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351: 1206-17.
11. Lampertico P, Viganò M, Di Costanzo GG, et al,. Randomised study comparing 48 and 96 weeks peginterferonα-2a therapy in genotype D HBeAg-negative chronic hepatitis B. Gut 2013; 62: 290-8.
12. Liaw YF, Jia JD, Chan HL, et al,. Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C. Hepatology 2011; 54: 1591-9.
13. Ge D, Fellay J, Thompson AJ, et al,. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
14. Suppiah V, Maldovam M, Ahlenstiel G, et al,. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009; 41: 1100-4.
15. Tanaka Y, Nishida N, Sugiyama M, et al,. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41: 1105-9.
16. Rauch A, Kutalik Z, Descombes P, et al,. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010; 138: 1338-45.
17. Thomas DL, Thio CL, Martin MP, et al,. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461: 798-801.
18. Wang FS,. Current status and prospects of studies on human genetic alleles associated with hepatitis B virus infection. World J Gastroenterol 2003; 9: 641-4.
19. Kamatani Y, Wattanapokayakit S, Ochi H, et al,. A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians. Nat Genet 2009; 41: 591-5.
20. Mbarek H, Ochi H, Urabe Y, et al,. A genome-wide association study of chronic hepatitis B identified novel risk locus in a Japanese population. Hum Mol Genet 2011; 20: 3884-92.
21. Nishida N, Sawai H, Matsuura K, et al,. Genome-wide association study confirming association of HLA-DP with protection against chronic hepatitis B and viral clearance in Japanese and Korean. PLoS ONE 2012; 7: e39175.
22. Liu L, Li J, Yao J, et al,. A genome-wide association study with DNA pooling identifies the variant rs11866328 in the GRIN2A gene that affects disease progression of chronic HBV infection. Viral Immunol 2011; 24: 397-402.
23. An P, Winkler C, Guan L, et al,. A common HLA-DPA1 variant is a major determinant of hepatitis B virus clearance in Han Chinese. J Infect Dis 2011; 203: 943-7.
24. Li J, Yang D, He Y, et al,. Associations of HLA-DP variants with hepatitis B virus infection in southern and northern Han Chinese populations: a multicenter case-control study. PLoS ONE 2011; 6: e24221.
25. Wang L, Wu XP, Zhang W, et al,. Evaluation of genetic susceptibility loci for chronic hepatitis B in Chinese: two independent case-control studies. PLoS ONE 2011; 6: e17608.
26. Cheng HR, Liu CJ, Tseng TC, et al,. Host Genetic Factors Affecting Spontaneous HBsAg Seroclearance in Chronic Hepatitis B Patients. PLoS ONE 2013; 8: e53008.
27. Seto WK, Wong DK, Kopaniszen M, et al,. HLA-DP and IL28 polymorphisms: influence of host genome on hepatitis B surface antigen seroclearance in chronic hepatitis B. Clin Infect Dis 2013; 56: 1695-703.
28. Fletcher GJ, Samuel P, Christdas J, et al,. Association of HLA and TNF polymorphisms with the outcome of HBV infection in the South Indian population. Genes Immun 2011; 12: 552-8.
29. Tseng TC, Yu ML, Liu CJ, et al,. Effect of host and viral factors on hepatitis B e antigen-positive chronic hepatitis B patients receiving pegylated interferon alpha-2a therapy. Antivir Ther 2011; 16: 629-37.
30. Sonneveld MJ, Wong VW, Woltman AM, et al,. Polymorphisms near IL28B and serologic response to peginterferon in HBeAg-positive patients with chronic hepatitis B. Gastroenterology 2012; 142: 513-20.
31. Wu X, Xin Z, Zhu X, et al,. Evaluation of susceptibility locus for response to interferon-alpha based therapy in chronic hepatitis B patients in Chinese. Antiviral Res 2012; 93: 297-300.
32. Zhang Q, Lapalus M, Asselah T, et al,. IFNL3 (IL28B) polymorphism does not predict long-term response to interferon therapy in HBeAg-positive chronic hepatitis B patients. J Viral Hepat 2013; doi: 10.1111/jvh.12177 [Epub ahead of print].
33. Lampertico P, Viganò M, Cheroni C, et al,. IL28B polymorphisms predict interferon-related hepatitis B surface antigen seroclearance in genotype D hepatitis B e antigen-negative patients with chronic hepatitis B. Hepatology 2013; 57: 890-6.
34. Fischer J, Bohm S, Scholz M, et al,. Combined effects of different interleukin-28B gene variants on the outcome of dual combination therapy in chronic hepatitis C virus type 1 infection. Hepatology 2012; 55: 1700-10.
35. Lampertico P, Galmozzi E, Colombo M,. Studies of IL28B genotype and response to peginterferon in chronic hepatitis B should be stratified by HBV genotype. Hepatology 2013; 57: 1283-4.
36. Brouwer WP, Arends P, Rijckborst V, et al,. Polymorphisms near the IL28B gene are not associated with response to peginterferon in HBeAg-negative chronic hepatitis B patients. J Hepatol 2013; 58: S299.
37. Holmes JA, Nguyen T, Ratnam D, et al,. IL28B genotypes is not useful for predicting treatment outcomes in Asian chronic hepatitis B patients treated with pegylated-interferon-α. J Gastroenterol Hepatol 2013; 28: 861-6.
38. de Niet A, Takkenberg RB, Benayed R, et al,. Genetic variation in IL28B and treatment outcome in HBeAg-positive and -negative chronic hepatitis B patients treated with Peg interferon alfa-2a and adefovir. Scand J Gastroenterol 2012; 47: 475-81.
39. Mangia A, Santoro R, Mottola L, et al,. Lack of association between IL28B variants and HBsAg clearance after interferon treatment. J Hepatol 2011; 54: S525.
40. Yan Z, Tan S, Dan Y, et al,. Relationship between HLA-DP gene polymorphisms and clearance of chronic hepatitis B virus infections: case-control study and meta-analysis. Infect Genet Evol 2012; 12: 1222-8.
41. Zhang XL, Ni XC, Jia JH, et al,. Association of the rs3077 and rs9277535 polymorphisms in HLA-DP with hepatitis B virus infection and spontaneous clearance: a meta-analysis. Scand J Gastroenterol 2013; 48: 736-44.